美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

291.47

-4.9900-1.68%

盘后：291.470.00000.00%16:39 EDT

成交量：17.12万

成交额：4,989.66万

市值：345.83亿

市盈率：-78.71

高：293.17

开：289.73

低：287.00

收：296.46

数据加载中...

总览公司新闻公告

30天通关！NMPA再掀审批革命

7月14日百济神州-UAH溢价达62.22%，位居AH股溢价率第70位

2025年医保政策与产业动态：产业布局升级与行业监管强化

东风已至！创新药，将迎历史性拐点？

百济神州暗藏杀招

百奥赛图与百济神州深化合作达成抗体分子全球许可协议

百济神州7月10日成交额为5230.17万美元

这款国产 PD-1 在海外又有新消息

Insight数据库

医保目录调整进展；百济神州达成一协议｜21健讯Daily

21世纪经济报道

百济神州：欧盟委员会批准百泽安联合化疗用于鼻咽癌患者一线治疗

南方财经网

百济神州7月9日成交额为9172.04万美元

百奥赛图与百济神州达成抗体分子许可协议，加速创新药物开发

美国商业资讯

百济神州美股涨逾3%

每日经济新闻

美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高

百济神州7月8日成交额为6492.56万美元

又有2款创新药拟纳入优先审评，来自百济神州、艾力斯

刚刚，原百济神州大中华区CFO去向曝光！

一款国产抗癌药，“少卖”570亿

中国企业家杂志

百济神州 DLL3/CD3 双抗拟纳入优先审评

Insight数据库

百济神州：CDK4抑制剂展现出优异早期疗效信号后续将进入注册临床研究阶段

天风证券股份有...

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":291.47,"timestamp":1753473600000,"preClose":296.46,"halted":0,"volume":171194,"hourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"休市中","change":-4.99,"latestTime":"07-25 16:00:00 EDT","open":289.73,"high":293.165,"low":287,"amount":49896623.98421,"amplitude":0.020795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":296.46,"preHourTrading":{"tag":"盘前","latestPrice":291,"preClose":296.46,"latestTime":"09:28 EDT","volume":38,"amount":11165.538480000001,"timestamp":1753450080032},"postHourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"volumeRatio":0.40463067027862526,"impliedVol":0.4268,"impliedVolPercentile":0.4714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.40463067027862526,"shares":118650120,"dividePrice":0,"high":293.165,"amplitude":0.020795,"preClose":296.46,"low":287,"week52Low":155.75,"pbRate":"9.88","psRate":"8.28","week52High":300,"institutionHeld":0,"latestPrice":291.47,"eps":-3.70325,"divideRate":0,"volume":171194,"delay":0,"ttmEps":-3.70325,"open":289.73,"prevYearClose":184.71,"prevWeekClose":294.55,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.55,"twentyDayClose":254.49,"sixtyDayClose":249.77,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551134532","title":"30天通关！NMPA再掀审批革命","url":"https://stock-news.laohu8.com/highlight/detail?id=2551134532","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551134532?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 09:03","pubTimestamp":1752541434,"startTime":"0","endTime":"0","summary":"近期，NMPA发布《优化创新药临床试验审评审批有关事项》，提出将创新药临床试验默示许可的审评时限由60日压缩至30日。与NMPA推进的“临床快审批”形成合力，中国创新药正在迎来“研发—审批—支付”三位一体政策闭环的新格局。于中国药企而言，30日通道的设立无疑是一次重大制度红利。在美国，FDA自1997年起即实行IND 30天审评制，强调申报资料完整性、临床试验设计合理性及申办方资质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","06160","ONC"],"gpt_icon":0},{"id":"2551909815","title":"7月14日百济神州-UAH溢价达62.22%，位居AH股溢价率第70位","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909815?lang=zh_cn&edition=fundamental","pubTime":"2025-07-14 16:43","pubTimestamp":1752482632,"startTime":"0","endTime":"0","summary":"7月14日，上证指数涨0.27%，收报3519.65点，恒生指数涨0.26%，收报24203.32点。当日收盘，百济神州-UA股报225.94元，跌幅1.72%，H股报152.5港元，下跌1.04%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526","06160"],"gpt_icon":0},{"id":"2551130912","title":"2025年医保政策与产业动态：产业布局升级与行业监管强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130912","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551130912?lang=zh_cn&edition=fundamental","pubTime":"2025-07-13 08:05","pubTimestamp":1752365100,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，随着国家医疗保障体系的不断完善，2025年医保相关政策及医药产业发展呈现显著变化。国家医保局、药监局等机构通过政策引导与严格监管，进一步优化药品供给结构，并强化了对违法违规行为的打击力度。数据显示，2025年目录调整将直接影响超万种药品的市场准入资格。总结2025年医保政策与产业布局呈现多维度深化态势：目录动态调整优化资源配置、监管强化保障行业规范、资本助力推动技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","ONC","06160","BK0239","688235"],"gpt_icon":0},{"id":"2550991907","title":"东风已至！创新药，将迎历史性拐点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2550991907","media":"浩海投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550991907?lang=zh_cn&edition=fundamental","pubTime":"2025-07-12 14:03","pubTimestamp":1752300180,"startTime":"0","endTime":"0","summary":"像百济神州2024年总营收同比大增56.2%至272亿元，亏损也收窄到49.78亿元，多家券商预计2025年百济神州会迎来利润转正的历史性拐点。长期来看，中国仍将是全球创新药市场的主要引擎。根据行业预测，2030年中国创新药整体销售额将突","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712150044a4462ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712150044a4462ca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","688506","06160","09995","BK1583","LU2488822045.USD","688235","600276","LU2328871848.SGD","01801","LEGN","LU1969619763.USD","06978","HCM","688331","BK1161","01276","ONC","BK1574","00013","09926","01530","BK1589"],"gpt_icon":0},{"id":"2550673969","title":"百济神州暗藏杀招","url":"https://stock-news.laohu8.com/highlight/detail?id=2550673969","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550673969?lang=zh_cn&edition=fundamental","pubTime":"2025-07-12 07:31","pubTimestamp":1752276667,"startTime":"0","endTime":"0","summary":"而另一边，“创新药一哥”百济神州已经明确表示即将“上岸”：预计将实现2025年全年GAAP经营利润为正，经营活动产生正现金流。然而，当行业目光聚焦于血液瘤产品的锋芒时，百济神州的实体瘤管线却如深海暗流般积蓄能量，爆发在即。01全面出击实体瘤领域也是百济神州的主要引擎之一。2024年，百济交出了一份令市场满意的业绩答卷。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712073404a445a3ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712073404a445a3ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK0239","688235"],"gpt_icon":0},{"id":"2550986727","title":"百奥赛图与百济神州深化合作 达成抗体分子全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2550986727","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550986727?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 14:57","pubTimestamp":1752217023,"startTime":"0","endTime":"0","summary":"百奥赛图近日宣布，与百济神州就抗体分子达成全球许可协议。此次合作是在百济神州已获百奥赛图RenMice®全人抗体平台授权的基础上，进一步拓展至具体抗体分子领域的授权许可，体现了双方在抗体研发方向上的持续协同与深入布局。此次协议的签署不仅强化了双方在创新生物药领域的合作关系，也显示出百奥赛图技术平台在全球新药开发中的重要价值。通过资源共享与优势互补，双方有望加速推进抗体药物的全球化开发进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","688235","ONC"],"gpt_icon":0},{"id":"2550607433","title":"百济神州7月10日成交额为5230.17万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550607433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550607433?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 12:39","pubTimestamp":1752208793,"startTime":"0","endTime":"0","summary":"美东时间2025年7月10日，百济神州成交额为5230.17万美元，成交额较昨日减少42.98%，当日成交量为20.68万股。百济神州于2025年7月10日跌0.9%，报253.39美元，该股过去5个交易日涨3.71%，年初至今涨37.18%，过去60日涨10.0%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711123957a443ef51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711123957a443ef51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2550677795","title":"这款国产 PD-1 在海外又有新消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2550677795","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550677795?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 08:18","pubTimestamp":1752193081,"startTime":"0","endTime":"0","summary":"替雷利珠单抗联合化疗组中位 PFS 为 9.2 个月，而安慰剂联合化疗组为 7.4 个月。额外 12 个月随访更新分析显示，有效性结果与期中分析结果一致。替雷利珠单抗联合化疗总体耐受性良好，未发现新的安全性信号。替雷利珠单抗是百济神州自主研发的 PD-1 抑制剂，2019 年 12 月在国内获批，2023 年 9 月，替雷利珠单抗获得欧盟批准，用于治疗特定类型的食管鳞状细胞癌，成为 PD-1 领域首款“出海”产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2550672907","title":"医保目录调整进展；百济神州达成一协议｜21健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2550672907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550672907?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 07:47","pubTimestamp":1752191224,"startTime":"0","endTime":"0","summary":"政策动向“两保”目录调整方案发布7月10日，国家医保局正式发布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507113453905588.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113453905588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","BK1583","LU2328871848.SGD","06160","BK4526","ONC","BK4139","LU1969619763.USD","BK1500","LU0307460666.USD","BK1588","BK1161"],"gpt_icon":0},{"id":"2550641478","title":"百济神州：欧盟委员会批准百泽安联合化疗用于鼻咽癌患者一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641478","media":"南方财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550641478?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 18:39","pubTimestamp":1752143991,"startTime":"0","endTime":"0","summary":"7月10日，百济神州宣布，欧盟委员会（EC）已批准百泽安?（替雷利珠单抗）联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或复发性鼻咽癌（NPC）成年患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507103453490572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1500","06160","BK1161","BK4139","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","ONC","BK1588","LU0307460666.USD","BK4526"],"gpt_icon":0},{"id":"2550694920","title":"百济神州7月9日成交额为9172.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550694920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550694920?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 12:37","pubTimestamp":1752122269,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，百济神州成交额为9172.04万美元，成交额较昨日增加41.27%，当日成交量为36.11万股。百济神州于2025年7月9日涨4.59%，报255.69美元，该股过去5个交易日涨4.3%，年初至今涨38.43%，过去60日涨22.74%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2550661203","title":"百奥赛图与百济神州达成抗体分子许可协议，加速创新药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2550661203","media":"美国商业资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550661203?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1583","BK1500","02315","688235","LU0307460666.USD","BK1161","BK1574","BK1588","LU0588546209.SGD","ONC","LU1969619763.USD","06978","LU2328871848.SGD"],"gpt_icon":0},{"id":"2550659831","title":"百济神州美股涨逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659831","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550659831?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 22:06","pubTimestamp":1752069960,"startTime":"0","endTime":"0","summary":"每经AI快讯，7月9日，百济神州美股涨逾3%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","LU2328871848.SGD","ONC","LU0307460666.USD","688235","LU1969619763.USD","BK1500","BK4139","LU0588546209.SGD","06160","BK0239","BK1588","BK1161","BK1583"],"gpt_icon":0},{"id":"2550165585","title":"美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550165585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550165585?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报252.97美元。尤其，中国创新药License-out交易额激增，2024年海外授权首付款31.6亿美元，交易总额511亿美元，联邦制药、恒瑞医药等多笔大额授权刷新纪录，全球BD交易占比升至30%。2025年一季度，海外授权总额再创455亿美元纪录，并且已经接近2024年全年水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","LU0307460666.USD","BK1588","BK4139","LU2328871848.SGD","LU0588546209.SGD","BK0239","ONC","LU1969619763.USD","BK1500","BK1574","06978","BK1583","688235","BK4526","BK1161","06160"],"gpt_icon":0},{"id":"2550504187","title":"百济神州7月8日成交额为6492.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550504187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550504187?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 12:35","pubTimestamp":1752035720,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，百济神州成交额为6492.56万美元，成交额较昨日减少16.17%，当日成交量为26.57万股。百济神州于2025年7月8日涨1.44%，报244.47美元，该股过去5个交易日涨0.99%，年初至今涨32.35%，过去60日涨18.49%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2550276505","title":"又有2款创新药拟纳入优先审评，来自百济神州、艾力斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2550276505","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550276505?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 10:44","pubTimestamp":1752029048,"startTime":"0","endTime":"0","summary":"此次在中国拟纳入优先审评，将加速其在中国的上市进程，为中国患者带来福音。优先审评是 CDE 推出的加速药物获批上市的重要政策之一。此次百济神州的注射用塔拉妥单抗和艾力斯的甲磺酸伏美替尼片拟纳入优先审评，将有助于它们更快地进入市场，为癌症患者带来新的生机，推动我国肿瘤治疗领域的进一步发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","06160","688235","688578","BK4526"],"gpt_icon":0},{"id":"2550284503","title":"刚刚，原百济神州大中华区CFO去向曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550284503","media":"CFO职业圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550284503?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 10:14","pubTimestamp":1752027296,"startTime":"0","endTime":"0","summary":"时隔4个月，他的新职位终于公布。详见《重磅！百济神州大中华区CFO离职》。加入亚盛医药之前，黄智先生担任百济神州大中华区和亚太区首席财务官、全球技术运营和全球商业财务负责人。在百济任职期间，他通过完整的全面预算管理及合理的全球布局资源优化，持续改善公司财务状况。据Veet Misra的领英资料，其工作经历详细如下：温馨提示关注并星标“CFO职业圈”，不错过每一篇新推送！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2550571442","title":"一款国产抗癌药，“少卖”570亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2550571442","media":"中国企业家杂志","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550571442?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 08:00","pubTimestamp":1752019249,"startTime":"0","endTime":"0","summary":"6月2日，美国药企BMS与德国药企BNT宣布达成战略合作：双方将共同开发双抗药物BNT327，交易总金额高达90亿美元。在许多投资者看来，才一年多时间，这款药就溢价了80亿美元量级，普米斯“低价卖青苗”，被中间商赚了差价。最具代表性的企业是再鼎医药，一度通过密集引进14款药物，先后在美国、中国香港上市，市值曾突破千亿港元，股价超越腾讯，成为“最贵港股”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","01530","688235","BK4588","02162","BK4505","09995","06998","BK4585","600276","BK4139","688321","06160","ONC","09926","688331","09688","LEGN","01276","02696"],"gpt_icon":0},{"id":"2549510933","title":"百济神州 DLL3/CD3 双抗拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2549510933","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549510933?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 17:11","pubTimestamp":1751965869,"startTime":"0","endTime":"0","summary":"7 月 8 日，CDE 官网显示，百济神州申报的注射用塔拉妥单抗拟纳入优先审评，用于既往接受过至少 2 线治疗失败的广泛期小细胞肺癌成人患者的治疗。2025 年 5 月，百济神州宣布，与安进公司在中国联合开展的注射用塔拉妥单抗2 期临床研究 DeLLphi-307 已取得积极结果。基于 DeLLphi-301、DeLLphi-304 和 DeLLphi-307 研究所获得的积极结果，塔拉妥单抗有望为中国 SCLC 患者的二线、三线及后线治疗提供新的用药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","06160","LU0307460666.USD","LU0588546209.SGD","BK1500","BK1588","LU1969619763.USD","LU2328871848.SGD","ONC","688235","BK1161"],"gpt_icon":0},{"id":"2549515128","title":"百济神州：CDK4抑制剂展现出优异早期疗效信号 后续将进入注册临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2549515128","media":"天风证券股份有...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549515128?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 15:52","pubTimestamp":1751961140,"startTime":"0","endTime":"0","summary":"百济神州的CDK4 抑制剂BGB-43395 进度处于前列，有望成为全球第二款进入注册临床阶段的CDK4 抑制剂根据公司指引，BGB-43395 预计在未来的 6-12 个月内进入注册临床阶段。CDK4 抑制剂BGB-43395 在多个体内外药效评估中均展现出BIC 潜力BGB-43395 相较现有CDK4/6 抑制剂具有更高选择性。百济神州的BGB-43395 体内药代动力学数据符合预期，药效学活性强效。CDK4 抑制剂BGB-43395 具有更优抑制效力。所以对同靶点药物，百济神州的CDK4i 来说，3 个月的中位随访时间还未到中位起效时间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","06160","ONC","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-25","current":-89.648478,"percent":0.003448,"low":-89.808695,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"high":-19.234246,"avg":-41.089589,"sd":19.328162,"marketCap":35175014575},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575}],"updateTime":1753563962847}}}